
Disease subset
Status of disease, treatment phase
MoAb, treatment program
Clinical studies
BCP ALL (Ph-, Ph+)
Relapsed/ Refractory
Inotuzumab ozogamicin (CD22), single agent
Phase II trials (MDACC, DFCI)
Ongoing phase III trial (International)
Inotuzumab ozogamicin (CD22) plus chemotherapy
Phase II trial (MDACC)
Blinatumomab (CD19), single agent
Pilot trial (GMALL), confirmatory phase II trial (International)
Ongoing phase III trial in Ph- ALL (International)
Ongoing phase II trial in Ph+ ALL (International)